2025
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or CAR T- cell therapy: An ASTCT Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines
Munshi P, Olin R, Wall S, McCurdy S, Al-Juhaishi T, Baker J, Bhatt V, Chokr N, Dahi P, DeFilipp Z, Espinoza-Gutarra M, Farhan S, Gowda L, Hamilton B, Inamoto Y, Jayani R, Kharfan-Dabaja M, Lin R, Meyers G, Mishra A, Murthy H, Nawas M, Rosko A, Ruiz M, Sorror M, Sung A, Carpenter P, Hamadani M, Artz A. US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or CAR T- cell therapy: An ASTCT Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines. Transplantation And Cellular Therapy 2025 PMID: 39961473, DOI: 10.1016/j.jtct.2025.02.014.Peer-Reviewed Original ResearchHematopoietic cell transplantationT-cell therapyCAR-T cell therapyCAR-TCell transplantationGeriatric assessmentCellular therapyChimeric antigen T-cell therapyAmerican Society for TransplantationPromote risk stratificationAllo-HCTRisk stratificationCell therapyOlder patientsRoutine GAOlder adultsGa uptakeTherapyPhysician practice patternsTransplantationPractice patternsClinical support staffCross-sectional surveyPhysician membersDomain of GA
2024
A multi‐institutional survey of apheresis services among institutions in the United States
Yurtsever N, Jacobs J, Booth G, Schwartz J, Park Y, Woo J, Lauro D, Torres S, Ward D, Stephens L, Allen E, Tormey C, Adkins B. A multi‐institutional survey of apheresis services among institutions in the United States. Journal Of Clinical Apheresis 2024, 39: e22138. PMID: 38979705, DOI: 10.1002/jca.22138.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeRed blood cell exchangeCell collectionSpectra Optia apheresis systemMulti-institutional surveyHematopoietic progenitor cell collectionProgenitor cell collectionUS academic centersCAR-TPlasma exchangeApheresis therapyGene therapyTransfusion medicine serviceCellular therapyApheresis practiceApheresis systemCell exchangeAcademic medical centerClinical trialsAcademic centersHPC-AApheresisMedical CenterTherapyCoronavirus disease 2019Finding Your CAR The Road Ahead for Engineered T Cells
Chen P, Raghunandan R, Morrow J, Katz S. Finding Your CAR The Road Ahead for Engineered T Cells. American Journal Of Pathology 2024, 194: 1409-1423. PMID: 38697513, PMCID: PMC11284763, DOI: 10.1016/j.ajpath.2024.04.002.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorCAR-T cellsAdoptive cellular therapyEngineered T cellsT cellsCellular therapyTumor cellsInfusion of CAR T cellsChimeric antigen receptor T cellsCAR-T cell cytotoxicityCAR-T cell persistenceCAR-T cell therapyT cell persistenceT-cell therapyT cell cytotoxicityTarget tumor antigensCytokine release syndromePathology laboratoryEvaluate side effectsTarget specific antigensTarget antigen identificationTransformative immunotherapyTumor antigensAntigen lossTumor microenvironmentCellular therapeutics and immunotherapies in wound healing – on the pulse of time?
Huelsboemer L, Knoedler L, Kochen A, Yu C, Hosseini H, Hollmann K, Choi A, Stögner V, Knoedler S, Hsia H, Pomahac B, Kauke-Navarro M. Cellular therapeutics and immunotherapies in wound healing – on the pulse of time? Military Medical Research 2024, 11: 23. PMID: 38637905, PMCID: PMC11025282, DOI: 10.1186/s40779-024-00528-5.Peer-Reviewed Original ResearchConceptsStandard of careChronic wound healing disordersLocal wound irrigationWound healingChronic inflammatory microenvironmentFree flap techniqueWound healing disordersChronic woundsGenetic risk profilesPhysiological wound healingAdequate blood supplySurgical debridementFlap techniqueCellular therapyCurrent therapiesHealing disordersInflammatory microenvironmentWound irrigationNon-healing woundsCellular therapeuticsGeneral anesthesiaFormation of biofilmsWound debridementSkin graftsImmunotherapyImmune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions
Knoedler L, Dean J, Diatta F, Thompson N, Knoedler S, Rhys R, Sherwani K, Ettl T, Mayer S, Falkner F, Kilian K, Panayi A, Iske J, Safi A, Tullius S, Haykal S, Pomahac B, Kauke-Navarro M. Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions. Frontiers In Immunology 2024, 15: 1372862. PMID: 38650942, PMCID: PMC11033354, DOI: 10.3389/fimmu.2024.1372862.Peer-Reviewed Original ResearchConceptsRegulatory myeloid cellsSolid organ transplantationVascularized composite allotransplantationMesenchymal stromal cellsT cellsTransplant patientsCellular therapyChimeric antigen receptor T cellsTransplant surgerySide effectsIncreased risk of malignancyProgression to chronic rejectionAcute rejection ratesPerioperative treatment strategiesRegulatory T cellsPromote immune toleranceRisk of malignancySystemic side effectsRelated side effectsCell typesImprove transplant survivalCAR-TCell therapy applicationsImmunosuppressive regimensChronic rejectionUsing Computed Tomography-Based Three-dimensional Modeling and Computer Navigation for Minimally Invasive Core Decompression and Adjuvant Orthobiologic Therapy of Femoral Head Avascular Necrosis
Feizi A, Bell C, Roytman G, Park N, Wang A, Tommasini S, Wiznia D. Using Computed Tomography-Based Three-dimensional Modeling and Computer Navigation for Minimally Invasive Core Decompression and Adjuvant Orthobiologic Therapy of Femoral Head Avascular Necrosis. Arthroplasty Today 2024, 26: 101337. PMID: 38497084, PMCID: PMC10940782, DOI: 10.1016/j.artd.2024.101337.Peer-Reviewed Original ResearchFemoral head avascular necrosisAvascular necrosisSurgical techniqueCore decompressionBone marrow aspirate concentrateDelay disease progressionOutcome of core decompressionAdjuvant therapyCellular therapyAspirate concentrateDisease progressionFemoral head collapseImprove outcomesLesionsDebilitating conditionTherapyComputer navigationNecrosisDecompressionHead collapseThree-dimensional modelFemoral head
2022
Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure
Qu R, Kluger Y, Yang J, Zhao J, Hafler D, Krause D, Bersenev A, Bosenberg M, Hurwitz M, Lucca L, Kluger H. Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure. Molecular Cancer 2022, 21: 219. PMID: 36514045, PMCID: PMC9749221, DOI: 10.1186/s12943-022-01688-5.Peer-Reviewed Original ResearchConceptsAdoptive cell therapySingle-cell analysisDepth single-cell analysisSingle-cell RNAACT productsDisease progressionT-cell receptor sequencingCell therapyFamily genesFeatures of exhaustionMultiple tumor typesCell expansionGenesNew clonotypesTIL preparationsClonal cell expansionCytokine therapyTreatment failureSerial bloodClonesEffector functionsSerial samplesTumor typesCellular therapyTherapyImmunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar S, Shum E, Grello C, Lau S, Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers In Oncology 2022, 12: 877594. PMID: 35992832, PMCID: PMC9382405, DOI: 10.3389/fonc.2022.877594.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint blockadeProgression-free survivalCell lung cancerLung cancerAnti-cytotoxic T-lymphocyte-associated protein 4 antibodyAnti-programmed death-1 antibodyDeath-1 antibodyFuture of immunotherapyOverall survival benefitProtein 4 antibodyViable therapeutic approachIdentification of biomarkersFree survivalCheckpoint blockadeDurable responsesSurvival benefitModulating therapiesCombination therapyClinical trialsTherapeutic approachesImmunotherapyFuture careLigand antibodyCellular therapymTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis
Eskandari SK, Allos H, Al Dulaijan B, Melhem G, Sulkaj I, Alhaddad JB, Saad AJ, Deban C, Chu P, Choi JY, Kollar B, Pomahac B, Riella LV, Berger SP, Sanders JSF, Lieberman J, Li L, Azzi JR. mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis. Frontiers In Immunology 2022, 13: 899975. PMID: 35757726, PMCID: PMC9229986, DOI: 10.3389/fimmu.2022.899975.Peer-Reviewed Original ResearchConceptsRegulatory T cellsT cellsHuman regulatory T cellsHost THumanized mouse modelPro-apoptotic pathwaysSkin allotransplantationClinical efficacyImmunosuppressive potencyIntracytoplasmic expressionTransplant fieldMouse modelCellular therapyHigh expressionTarget cellsRapamycin complex 1Lysosomal granulesFunctional effectsMechanistic targetPatientsApoptosisC-JunGranzymesDrug targetsS6K21 Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular Therapy
Schoettler M, Spencer K, Lutterman D, Rumbika S, Haight A, Stenger E, Parikh S, Qayed M, Watkins B, Krishnamurti L, Williams K, Chonat S. 21 Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular Therapy. Transplantation And Cellular Therapy 2022, 28: s20-s21. DOI: 10.1016/s2666-6367(22)00182-8.Peer-Reviewed Original ResearchTranslating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
Bewersdorf J, Abdel-Wahab O. Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. Genes & Development 2022, 36: 259-277. PMID: 35318270, PMCID: PMC8973851, DOI: 10.1101/gad.349368.122.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid leukemiaAnti-Tim-3 antibodiesPathogenesis of acute myeloid leukemiaTargeting of acute myeloid leukemiaMolecular targeted approachesUnmet medical needAnti-CD47IDH1/2 inhibitorsHematologic malignanciesSplicing factor mutationsCellular therapyPreclinical meansImmune targetsTET2</i>FDA approvalTrispecific antibodyMenin inhibitionMedical needLeukemiaAntibodiesIDH1/2MalignancyTherapyPatients
2021
Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra
Montanari F, Orjuela-Grimm M. Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra. Current Hematologic Malignancy Reports 2021, 16: 52-60. PMID: 33544319, PMCID: PMC8117403, DOI: 10.1007/s11899-021-00606-8.Peer-Reviewed Original ResearchConceptsAdult age spectrumCombination of immunochemotherapyRecent FindingsClinical trialsRisk-stratified strategiesTreatment-related toxicityLarge prospective studiesFuture therapeutic approachesNovel therapeutic strategiesNovel target therapiesLymphoproliferative disordersPediatric populationProspective studyRetrospective studyClinical algorithmTreatment paradigmTreatment strategiesTherapeutic approachesTherapeutic strategiesCellular therapyHeterogeneous groupPTLDTherapyDiseaseImmunochemotherapy
2020
Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis
Rubinstein S, Lynch R, Desai A, Stratton C, Jha A, Bakouny Z, Schmidt A, Sica R, Bhutani D, Shah D, Wall S, Lyman G, Kuderer N, Weiss M, Warner J, Stockerl-Goldstein K, Mesa R, Thompson M. Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis. Blood 2020, 136: 28-30. PMCID: PMC8330211, DOI: 10.1182/blood-2020-141937.Peer-Reviewed Original ResearchSevere COVID-19COVID-19 outcomesSevere COVID-19 outcomesCOVID-19 diagnosisHematologic malignanciesCOVID-19 treatmentNational Cancer InstituteBristol-Myers SquibbPerformance statusClinical outcomesSupplemental oxygenICU levelMechanical ventilationPoor outcomeCytotoxic therapyCOVID-19Cancer InstituteEastern Cooperative Oncology Group performance statusLaboratory-confirmed COVID-19Cellular therapySars-Cov-2 infectionSevere COVID-19 illnessCytotoxic systemic therapyTherapy-related immunosuppressionPoor performance statusDifferentiation of PTH-Expressing Cells From Human Pluripotent Stem Cells
Lawton BR, Martineau C, Sosa JA, Roman S, Gibson CE, Levine MA, Krause DS. Differentiation of PTH-Expressing Cells From Human Pluripotent Stem Cells. Endocrinology 2020, 161: bqaa141. PMID: 32810225, PMCID: PMC7505176, DOI: 10.1210/endocr/bqaa141.Peer-Reviewed Original ResearchIncorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902
Foss FM, Wang XV, Luger SM, Jegede O, Miller KB, Stadtmauer EA, Whiteside TL, Avigan DE, Gascoyne RD, Arber D, Wagner H, Strair RK, Hogan WJ, Sprague KA, Lazarus HM, Litzow MR, Tallman MS, Horning SJ. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion 2020, 60: 1867-1872. PMID: 32654201, PMCID: PMC7606221, DOI: 10.1111/trf.15798.Peer-Reviewed Original ResearchConceptsReduced intensity conditioning regimenIntensity conditioning regimenExtracorporeal photopheresisConditioning regimenChronic extensive GVHDTotal body irradiationChronic graftECOG-ACRINExtensive GVHDGVHD prophylaxisHost diseaseMycophenolate mofetilCell infusionMulticenter trialTolerogenic stateAggressive lymphomaBody irradiationMedian timeMyelodysplastic syndromeGrade 3Day 100PatientsCellular therapyConsecutive daysAdequate engraftment
2018
Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization
Fuchs A, Gliwiński M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Gołab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grześ D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers In Immunology 2018, 8: 1844. PMID: 29379498, PMCID: PMC5775516, DOI: 10.3389/fimmu.2017.01844.Peer-Reviewed Original ResearchAntigen-presenting cellsRegulatory cellsTolerogenic antigen-presenting cellsT regulatory (Treg) cellsClinical applicationPosttransplant complicationsTreg preparationsAllergic diseasesClinical trialsTregsEfficacious treatmentTreg productsCellular therapyStandardized reportingMedicinal productsDifferent preparationsCellsInvestigatorsCD4ComplicationsTherapyDiseaseTrials
2016
ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells
Boddupalli CS, Nair S, Gray SM, Nowyhed HN, Verma R, Gibson JA, Abraham C, Narayan D, Vasquez J, Hedrick CC, Flavell RA, Dhodapkar KM, Kaech SM, Dhodapkar MV. ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells. Journal Of Clinical Investigation 2016, 126: 3905-3916. PMID: 27617863, PMCID: PMC5096804, DOI: 10.1172/jci85329.Peer-Reviewed Original ResearchConceptsTissue-resident memory T cellsMemory T cellsT cellsTRM cellsCellular therapyAdoptive cellular therapyImmune-deficient micePotential cellular therapySP T cellsSide population cellsHuman T cellsPutative subsetsAdoptive transferDistinct gene expression profilesCell mobilizationImmune surveillanceQuiescent subsetPopulation cellsMiceTherapyQuiescent phenotypeDistinct subsetsMember 1Nuclear receptorsSignature genesPortal Venous Interventions: State of the Art
Madoff DC, Gaba RC, Weber CN, Clark TW, Saad WE. Portal Venous Interventions: State of the Art. Radiology 2016, 278: 333-353. PMID: 26789601, DOI: 10.1148/radiol.2015141858.Peer-Reviewed Original ResearchConceptsBalloon retrograde transvenous obliterationEnd-stage liver diseaseIntrahepatic portosystemic shunt placementPreoperative portal vein embolizationTransjugular intrahepatic portosystemic shunt placementPortal venous interventionsMajor hepatic resectionPortal vein embolizationPortosystemic shunt placementPortal venous systemRetrograde transvenous obliterationIslet cell transplantationHepatic resectionVein embolizationDiabetes mellitusVenous interventionsLiver diseaseShunt placementClinical manifestationsTransvenous obliterationCell transplantationVenous systemUntoward effectsLiver cancerCellular therapy
2015
Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation
Stenger E, Krishnamurti L, Galipeau J. Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation. BMC Immunology 2015, 16: 74. PMID: 26674007, PMCID: PMC4681052, DOI: 10.1186/s12865-015-0135-7.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationMesenchymal stromal cellsCell transplantationPost-hematopoietic cell transplantationStromal cellsHematopoietic stem cell engraftmentPre-clinical studiesStem cell engraftmentHost diseaseImmune reconstitutionClinical trialsAnimal modelsCell engraftmentMultipotent progenitor cellsImmune systemHSC engraftmentCellular therapyProgenitor cellsTransplantationEngraftmentTrialsDual effectCellsEarly evidenceGVHDVascular Platform to Define Hematopoietic Stem Cell Factors and Enhance Regenerative Hematopoiesis
Poulos MG, Crowley MJP, Gutkin MC, Ramalingam P, Schachterle W, Thomas JL, Elemento O, Butler JM. Vascular Platform to Define Hematopoietic Stem Cell Factors and Enhance Regenerative Hematopoiesis. Stem Cell Reports 2015, 5: 881-894. PMID: 26441307, PMCID: PMC4649106, DOI: 10.1016/j.stemcr.2015.08.018.Peer-Reviewed Original ResearchConceptsBM endothelial cellsHematopoietic stem cellsBone marrowDevelopment of therapiesAdult bone marrowCytokine profileMyeloablative regimensMyeloablative irradiationStem cell factorRegenerative hematopoiesisPerivascular cellsCellular therapyEndothelial cellsDisease statesCytokine supplementationVascular platformCell factorVascular nicheTherapyPrevious reportsStem cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply